[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"periodontal-inflammation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:periodontal-inflammation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,44,68,94,131,166,193,218,243],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100539890","hyaluronic-acid-and-polynucleotides-for-supra-bony-defects-100539890",false,"NCT06309719","Hyaluronic Acid and Polynucleotides for Supra-bony Defects","Characterizing the Healing of Periodontal Supra-bony Defects Treated With Hyaluronic Acid and Polynucleotides","Inclusion Criteria:\n\n* Systemically healthy males and females ≥18 years old\n* Stage III or IV periodontitis (Papapanou, Sanz et al. 2018)\n* Presence of supra-bony periodontal defects (i.e., defects where the base of the pocket is located coronal to the alveolar crest and characterized by a predominantly horizontal pattern of tissue destruction) confirmed clinically and radiographically at a minimum of two and a maximum of four adjacent teeth and with a probing pocket depth (PPD) \\> 5 mm, following non-surgical periodontal therapy (NSPT). If \\>4 adjacent teeth exhibited the above clinical and radiographic conditions, the four adjacent teeth showing the greatest overall loss of periodontal attachment were included. Wisdom teeth and second molars will not be considered for the study.\n\nIf defect presents with an intrabony component, this should be ≤2 mm.\n\n* Non-surgical periodontal treatment (step 1 and 2) completed within the previous 4 months\n* Full-mouth bleeding score (FMBS) and full-mouth plaque score (FMPS) ≤20%\n\nExclusion Criteria:\n\n* Teeth with degree III mobility\n* Multi-rooted teeth with grade ≥2 furcation involvement\n* Heavy smokers (≥10 cigarettes a day)\n* Untreated caries or endodontic lesions or abscesses on the teeth involved in the surgery\n* Previous periodontal surgery in the area selected for the study\n* History of conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures (e.g., mitral valve prolapse, artificial heart)\n* Antibiotic or anticoagulant therapy during the month preceding the baseline exam.\n* History of alcohol or drug abuse\n* Medical history that includes uncontrolled diabetes or hepatic or renal diseases, or other serious medical conditions that can have a negative impact on the periodontal condition\n* In treatment with medications that can severely affect bone metabolism and blood clot formation (e.g., anticoagulants, long-term corticosteroids, bisphosphonates, immunosuppressants)\n* Self-reported pregnancy or lactation.","ALL","18 Years",{"count":19,"type":20},24,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this pilot study is to describe the early wound healing molecular events and the vascularization pattern associated with the treatment of supra-bony defects with access flap alone or in association with a combined formulation of hyaluronic acid and polydeoxyribonucleotides gel.",[26,27,28,29,30],"Periodontal Diseases","Wound Heal","Periodontal Inflammation","Periodontal Pocket","Periodontal Attachment Loss","RECRUITING","2026-07-01",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":35},"2024-10-21",{"date":39,"type":20},"2026-12",{"name":41,"class":42},"Queen Mary University of London","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100593995","prf-as-adjunct-to-subgingival-instrumentation-in-step-2-periodontal-therapy-100593995","NCT07013682","PRF as Adjunct to Subgingival Instrumentation in Step 2 Periodontal Therapy","Platelet Rich Fibrin Adjunctive to Non-surgical Periodontal Therapy: a 6-month Split-mouth Randomized Controlled Clinical Trial","PRFSTEP2","Inclusion Criteria:\n\n* Men and women aged ≥ 18 years\n* Periodontitis stage II-IV, grade A\u002FB\u002FC, generalized\n* Presence of at least 20 teeth (excluding wisdom teeth)\n* Absence of removable dentures\n* Patients willing to provide written informed consent and to complete the 6- month study follow-up\n\nExclusion Criteria:\n\n* Patients already participating in other clinical trials\n* Periodontal treatment in the previous 12 months\n* Antibiotic treatment 3 months prior to study entry\n* Antibiotic prophylaxis required for dental treatment\n* Current use of any medication that may affect the clinical features of periodontitis\n* Pregnant\u002Flactating\n* Any condition that prevents venipuncture\n* Not willing to venous puncture\n* Current cancer treatment\n* History of radiation in the head-neck area",true,{"count":54,"type":20},20,[23],"Periodontitis is characterized by a chronic, multifactorial inflammatory process driven by dysbiotic plaque biofilms. It is recognized as the most common chronic inflammatory non-communicable disease in humans. The advanced and severe forms of periodontitis have an estimated prevalence of 7.4%, while milder forms can affect up to 50% of the population.\n\nIf left untreated, periodontitis can lead to tooth loss. However, it is largely preventable and treatable with mechanical non-surgical periodontal therapy. To improve periodontal healing and thus clinical attachment gain after non-surgical therapy, adjunctive bioactive formulations such as enamel matrix derivatives, sodium hypochlorite, locally delivered antimicrobials, or hyaluronic acid have recently been proposed. However, these agents are non-autologous formulations and expensive.\n\nPlatelet-rich fibrin (PRF) acts as a scaffold that inhibits the early migration of epithelial cells into the periodontal tissues. Its regenerative properties are primarily due to its ability to promote angiogenesis. This ability is attributed to the 3D fibrin matrix, which can simultaneously transport several cytokines and growth factors. These include vascular endothelial growth factor (VEGF), insulin growth factor (IGF), transforming growth factor β1 (TGF-β1) and platelet-derived growth factor (PDGF). PRF further shows antibacterial properties and accelerates soft tissue healing. So far PRF is not routinely used in periodontal non-surgical therapy.\n\nThe aim of this 6-month, split-mouth randomized clinical trial including 20 patients is to test whether PRF can improve the results after non-surgical therapy.",[58,28,30],"Periodontitis","2026-06-30",{"date":34,"type":35},{"date":62,"type":35},"2025-05-01",{"date":64,"type":20},"2027-12-24",{"name":66,"class":42},"University of Bern",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":67},"100631923","inflammation-in-clear-aligners-with-and-without-attachments-100631923","NCT07506993","Inflammation in Clear Aligners With and Without Attachments","Molar-Specific Inflammatory Biomarkers in Adolescents Using Clear Aligners With and Without Attachments","Inclusion Criteria:\n\n* orthodontic patient at the UNMC College of dentistry\n* clear aligner therapy\n\nExclusion Criteria:\n\n* pregnancy","14 Years","35 Years",{"count":78,"type":20},30,"OBSERVATIONAL","Problem: Clear aligner therapy is widely used in orthodontics due to improved periodontal outcomes compared to fixed appliances. However, composite attachments are frequently bonded to molars to enhance biomechanics, potentially creating plaque-retentive areas that may increase localized inflammatory responses. Currently, no studies have directly compared periodontal inflammatory biomarker levels in molars treated with clear aligners with versus without attachments. This gap limits understanding of the biological impact of attachments on periodontal tissues.Hypothesis:First molars treated with clear aligners and composite attachments will demonstrate higher levels of inflammatory biomarkers in gingival crevicular fluid (GCF) compared to molars treated with clear aligners without attachments. Biomarker levels are expected to be lower in the non-attachment group. Methods: This study will include 30 orthodontic patients divided into two groups (15 per group):1. Clear aligners with molar attachments 2. Clear aligners without molar attachments. GCF samples will be collected from first molars at a routine orthodontic appointment at the UNMC College of Dentistry Graduate Orthodontic Clinic. Primary biomarkers include IL-1β, IL-6, TNF-α, and MMP-8 measured via ELISA. Clinical periodontal parameters (Plaque Index, Gingival Index, Bleeding on Probing, Probing Depth) will also be recorded.",[28],[83,84],"inflammation","orthodontics","2026-06-12",{"date":87,"type":35},"2026-06-16",{"date":89,"type":35},"2026-05-01",{"date":91,"type":20},"2027-05-01",{"name":93,"class":42},"University of Nebraska",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":52,"sex":16,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":106,"conditions":107,"keywords":111,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":67},"100640692","circadian-clock-proteins-in-gingival-crevicular-fluid-of-individuals-with-and-without-circadian-rhythm-disruption-100640692","NCT07592052","Circadian Clock Proteins in Gingival Crevicular Fluid of Individuals With and Without Circadian Rhythm Disruption","Investigation of Circadian Clock Gene\u002FProteins in Individuals With and Without Disrupted Circadian Rhythm: A Prospective Cross-Sectional Clinical Study","Nursma-CIRC-HG","Inclusion Criteria:\n\n* Aged between 20 and 50 years\n* Systemically healthy\n* Diagnosed as periodontally healthy or with gingivitis based on clinical periodontal examination\n* Having at least 20 natural teeth in the oral cavity\n* Willing to provide written informed consent\n* Agreeing to participate in circadian rhythm assessment and completing the Morningness-Eveningness Questionnaire (MEQ) and Munich Chronotype Questionnaire (MCTQ)\n* Sleep duration of 6-9 hours per day\n* For periodontally healthy: PD \\\u003C=3 mm, BOP \\\u003C10%, CAL=0, no radiographic bone loss\n* For gingivitis: PD \\\u003C=3 mm, 10%\\\u003C=BOP\\\u003C=30%, CAL=0, no radiographic bone loss\n* For circadian rhythm disruption group: being a night-shift worker\n\nExclusion Criteria:\n\n* Use of antioxidant or melatonin supplements\n* Presence of any systemic disease\n* Use of antibiotics, anti-inflammatory drugs, or immunosuppressants within the past 3 months\n* Having received periodontal treatment within the past 6 months\n* Pregnancy or lactation\n* Use of tobacco or tobacco products\n* Presence of acute oral infection, abscess, or advanced periodontal disease\n* Currently undergoing orthodontic treatment or having fixed orthodontic appliances\n* Inability to comply with study procedures or refusal to provide informed consent\n* Self-reported sleep duration less than 6 hours or greater than 9 hours per day","20 Years","50 Years",{"count":105,"type":20},116,"This prospective cross-sectional clinical study aims to investigate the relationship between circadian rhythm disruption and periodontal inflammation by evaluating circadian clock protein levels, inflammatory (IL-1beta) and anti-inflammatory (IL-10) cytokine levels in gingival crevicular fluid (GCF) of individuals with and without circadian rhythm disruption.\n\nParticipants aged 20-50 years will be classified into four groups based on their circadian rhythm status (disrupted\u002Fnormal) and gingival health status (gingivitis\u002Fhealthy). Clinical periodontal parameters including plaque index, gingival index, bleeding on probing, and probing depth will be assessed. Circadian rhythm status will be determined using validated questionnaires (Morningness-Eveningness Questionnaire and Munich Chronotype Questionnaire). Night-shift workers will represent the circadian rhythm disruption group.\n\nGCF samples will be analyzed for circadian clock proteins (BMAL-1, CLOCK, PER-1, PER-2, PER-3, CRY-1, CRY-2, REV-ERB-beta, MTNR1B) and cytokines (IL-1beta, IL-10) using ELISA. Serum cortisol and melatonin levels will be measured for biochemical verification of circadian rhythm status.\n\nGingivitis groups will receive standard periodontal treatment and be re-evaluated at 2 weeks post-treatment. A total of 116 participants (29 per group) are planned for enrollment.",[108,109,28,110],"Gingivitis","Circadian Rhythm Disruption","Circadian Rhythm Sleep Disorder, Shift Work Type",[112,113,108,114,115,116,117,118,119,120],"Circadian rhythm","Periodontal health","Gingival crevicular fluid","Clock genes","BMAL1","Night shift work","IL-1beta","IL-10","Chronotype","NOT_YET_RECRUITING","2026-05-11",{"date":124,"type":35},"2026-05-18",{"date":126,"type":20},"2026-08-01",{"date":128,"type":20},"2027-03-01",{"name":130,"class":42},"Inonu University",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":21,"phases":141,"briefSummary":142,"conditions":143,"keywords":148,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":163,"locationsCount":4},"100639272","efficacy-and-safety-of-ha35-gel-for-post-dental-gingival-pain-and-swelling-100639272","NCT07584655","Efficacy and Safety of HA35 Gel for Post-Dental Gingival Pain and Swelling","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate Efficacy and Safety of Topical 10% 35 kDa Hyaluronan (HA35) Gel for Post-Dental Gingival Pain and Swelling","HA35","Inclusion Criteria:\n\n* Age 18-65 years, male or female\n* Experienced gingival pain and swelling within 12 hours after dental procedures\n* Baseline gingival pain NRS score ≥2\n* Able to independently complete pain and swelling assessments\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Severe periodontitis, uncontrolled diabetes, or immune dysfunction\n* Long-term use of analgesics or anti-inflammatory drugs\n* Known hypersensitivity to hyaluronan or gel components\n* Oral infection, ulceration, or severe mucosal injury at the application site\n* Pregnant or lactating women","65 Years",{"count":78,"type":20},[23],"This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of 10% high-concentration 35 kDa hyaluronan (HA35) gel delivered via gel-soaked cotton balls in patients with gingival pain and swelling after dental procedures. Eligible participants will gently chew and retain the gel-soaked cotton balls on the affected area for 30 minutes. The primary objectives are to assess changes in gingival pain and swelling at 1, 30, and 60 minutes after application. Safety and local oral tolerability will be evaluated throughout the observation period. This is a minimal-risk, non-pharmacological, non-invasive intervention.",[144,145,146,147,28],"Post-Dental Gingival Pain","Gingival Swelling","Postoperative Oral Pain","Dental Procedure-Related Discomfort",[149,150,137,151,152,145,153,154,155,156],"Hyaluronan","35 kDa Hyaluronan","Topical Gel","Gingival Pain","Dental Postoperative Care","Analgesia","Anti-Inflammation","Pilot Clinical Study","2026-05-07",{"date":159,"type":35},"2026-05-13",{"date":161,"type":20},"2026-06-01",{"date":126,"type":20},{"name":164,"class":165},"Nakhia Impex LLC","INDUSTRY",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":177,"conditions":178,"keywords":183,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":191,"leadSponsor":192,"locationsCount":4},"100639359","efficacy-and-safety-of-ha35-gel-for-mild-gingival-recession-and-periodontal-inflammation-100639359","NCT07577258","Efficacy and Safety of HA35 Gel for Mild Gingival Recession and Periodontal Inflammation","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate Efficacy and Safety of Topical 10% 35 kDa Hyaluronan (HA35) Gel for Mild Gingival Recession and Chronic Periodontal Inflammation","HA35-PERI","Inclusion Criteria:\n\n* Age 18-60 years, male or female\n* Clinically diagnosed with mild gingival recession (Miller Class I or II)\n* Chronic gingival pain, redness, swelling, or brushing-induced bleeding\n* Ability to complete self-assessments and comply with 42-day intervention\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Severe periodontitis, tooth mobility, or alveolar bone loss\n* Uncontrolled diabetes or immune dysfunction\n* Use of prescription periodontal medications within 2 weeks\n* Known hypersensitivity to hyaluronan or gel components\n* Oral infection, ulceration, or severe mucosal injury\n* Pregnant or lactating women","60 Years",{"count":78,"type":20},[23],"This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel in subjects with mild gingival recession and chronic periodontal inflammation. Eligible participants will apply the HA35 gel topically to the gingival and tooth surfaces twice daily for 42 consecutive days. The primary objectives are to assess changes in gingival recession, chronic gingival or radicular pain, gingival redness and swelling, and brushing-induced bleeding. Safety and local oral tolerability will be evaluated throughout the treatment period. This is a minimal-risk, non-pharmacological, non-invasive oral care intervention.",[179,28,180,181,182],"Mild Gingival Recession","Chronic Gingival Pain","Gingival Redness and Swelling","Gingival Bleeding",[149,150,137,184,185,152,182,186,187,156],"Gingival Recession","Periodontal Disease","Gingival Repair","Oral Care",{"date":189,"type":35},"2026-05-12",{"date":161,"type":20},{"date":126,"type":20},{"name":164,"class":165},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":21,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":67},"100473010","application-of-a-dental-dedicated-mri-in-the-diagnosis-of-temporomandibular-joint-disorders-tissue-alterations-related-to-third-molars-periapical-and-periodontal-inflammatory-diseases-and-implant-treatment-planning-100473010","NCT05439330","Application of a Dental-dedicated MRI in the Diagnosis of Temporomandibular Joint Disorders, Tissue Alterations Related to Third Molars, Periapical and Periodontal Inflammatory Diseases, and Implant Treatment Planning","Application of a Dental-dedicated MRI in the Diagnosis of Temporomandibular Joint Disorders, Tissue Alterations Related to Third Molars, Periapical and Periodontal Inflammatory Diseases, and Implant Planning","Inclusion Criteria (one of the following):\n\n* referred for CBCT imaging of at least one tooth for endodontic reasons\n* referred for intra-oral and\u002For panoramic imaging covering at least one molar tooth for periodontal reasons\n* referred for CBCT imaging of the TMJ (bilaterally)\n* referred for panoramic imaging of the third molar (retained\u002Fsemi-retained, uni- or bilateral), prior to treatment planning\n* referred for CBCT imaging prior to implant treatment\n\nExclusion Criteria:\n\n* younger than 18 years\n* unable to give consent\n* pregnant\n* pronounced claustrophobia\n* pacemakers or implanted defibrillators\n* metal shrapnel injuries of the eyes or MRI incompatible metallic inclusions or implants large tatoos\n* non-removable piercings",{"count":201,"type":20},470,[23],"The aim of the present study is to show that the use of 0.55T MRI combined with a \"dental\" coil produces images of sufficient diagnostic value to assess areas of interest in dentistry, and to compare MR images to traditional, dental-oriented radiographic images for diagnostic purposes.",[205,206,28,207,208],"TMJ","Apical Periodontitis","Retained Tooth","MRI","2026-04-28",{"date":211,"type":35},"2026-05-04",{"date":213,"type":35},"2022-09-01",{"date":215,"type":20},"2026-12-31",{"name":217,"class":42},"University of Aarhus",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":67},"100634170","characterization-of-jak1-and-jak2-activation-in-gingival-tissues-during-homeostasis-and-periodontitis-100634170","NCT07536204","Characterization of JAK1 and JAK2 Activation in Gingival Tissues During Homeostasis and Periodontitis","Unraveling the Role of JAK1 and JAK2 Pathway in Periodontitis: Drivers of Immunopathology and Possible Therapeutic Targets","Inclusion Criteria:\n\n* Adults\n* Sistemically healthy\n\nExclusion Criteria:\n\n* Active Maliganancy\n* History of radiation to the head-neck region\n* Chemotherapy or radiation within the last 5 years\n* History of hepatitis B\u002FC or HIV infection\n* Autoimmune diseases\n* Diagnosis of diabetes\n* Pregnancy or lactation\n* More than 3 hospitalizations over the last 3 years\n* Use of systemic antibiotics over the last 3 months\n* Use of systemic corticosteroids or immunosuppressants over the last 3 months\n* Use of cytokine therapy over the last 3 months\n* Use of large doses of pre\u002Fprobiotic supplements over the last 3 months\n* Smoke more than 10 cigarettes per day",{"count":78,"type":20},"The goal of this observational study is to examine JAK1\u002F2 pathway activation in gingival tissues from adults with healthy gingiva and those with inflamed gingiva (periodontitis). The main question it aims to answer is:\n\nIs the JAK1\u002F2 pathway overactivated in periodontitis compared to health?\n\nParticipants with healthy gingiva and periodontitis will donate gingival tissue to study the JAK1\u002F2 pathway. All participants wil receive diagnosis and treatment of the gingival condition.",[58,26,28,228,30],"Gingival Diseases",[230,231,58,232,233],"JAK1","JAK2","Gingiva","Inflammation","2026-04-10",{"date":236,"type":35},"2026-04-17",{"date":238,"type":35},"2023-06-01",{"date":240,"type":20},"2027-03-31",{"name":242,"class":42},"University of Chile",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":21,"phases":252,"briefSummary":253,"conditions":254,"keywords":255,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":43},"100556233","hyaluronic-acid-and-octenidine-gel-as-an-adjunct-to-non-surgical-periodontal-treatment-100556233","NCT06522438","Hyaluronic Acid and Octenidine Gel as an Adjunct to Non-surgical Periodontal Treatment","Early Healing Dynamics and Microbial Changes Following the Use of a Novel Thermosensitive Gel With Hyaluronic Acid and Octenidine as an Adjunct to Non-surgical Periodontal Treatment","Inclusion Criteria:\n\n* Male or female aged 18 and above\n* Engaged patients presenting with a Full Mouth Plaque Score (FMPS) of ≤ 20% within the 6 weeks prior to enrolment, or exhibiting a ≥ 50% reduction in plaque score from the initial screening visit.\n* Periodontitis stage III\u002FIV (grades A to C) with at least one site per quadrant with PPD ≥5mm, bleeding on probing and attachment loss ≥5mm\n* Willing to sign informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* Know hypersensitivity and\u002For allergy to any of the product's component (as per user leaflet)\n* Self-reported pregnancy or lactation\n* Smoking (current or in past 5 years), including e-cigarettes\u002Fvaping\n* Medical history including diabetes mellitus or other serious medical\u002F psychiatric conditions or transmittable diseases that according to the investigator may increase the risk associated with study participation\n* History of conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures or\u002Fand systemic antibiotic therapy during the 3 months preceding the baseline evaluation\n* In chronic treatment with anti-inflammatory (including corticosteroids), anticoagulants\u002Fantiplatelets (including aspirin), immunosuppressants or other medication that can severely impact wound healing\n* History of alcohol or drug abuse\n* Subgingival professional mechanical plaque removal (excluding not-extensive subgingival debridement as judged by the examining clinician) and\u002For surgical periodontal treatment within the last 12 months\n* Other severe acute or chronic medical or psychiatric condition or psychological disorder, including limited mental capacity or language skills such that study information could not be understood, informed consent could not be obtained, or simple instructions could not be followed, or any additional conditions which, in the judgement of the investigator, would make the subject inappropriate for entry into this trial",{"count":251,"type":20},26,[23],"This parallel-group, pilot study will test the hypothesis that the adjunctive use of a thermosensitive gel containing Hyaluronic Acid (HA) and Octenidine to non-surgical periodontal treatment (NSPT) will be able to modulate the early wound healing events. This will be assessed through the expression of specific gingival crevicular fluid markers, as well as by changes in gingival blood flow (assessed by laser speckle contrast imaging), bacterial load, soft tissues contour, clinical parameters and patient-reported outcomes.\n\nThe study will involve up to 26 patients and will take place at the Centre for Oral Clinical Research (COCR), at the Institute of Dentistry, Faculty of Medicine and Dentistry, Queen Mary University of London under The Royal London Dental Hospital, Barts Health NHS Trust. Patients will be randomised to receive either NSPT alone or NSPT+ HA and Octenidine gel, and will be followed up to 3 months after treatment.\n\nThe study will consist of 7- 8 visits.",[58,27,29,28,30],[256,257,258,259],"Hyaluronic Acid","Octenidine","Biomarkers","Non-surgical periodontal treatment","2026-02-03",{"date":262,"type":35},"2026-02-05",{"date":264,"type":35},"2025-06-03",{"date":266,"type":20},"2027-12-31",{"name":41,"class":42}]